148 related articles for article (PubMed ID: 18065924)
21. Can gadolinium be safely given in renal failure?
Weissleder R
AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
[No Abstract] [Full Text] [Related]
22. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium.
Cowper SE
Adv Dermatol; 2007; 23():131-54. PubMed ID: 18159899
[TBL] [Abstract][Full Text] [Related]
23. Nephrogenic systemic fibrosis: is gadolinium the missing piece to the puzzle?
Bennett LK; Garrett AL
Cutis; 2008 May; 81(5):421-6. PubMed ID: 18543594
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium deposition disease: Initial description of a disease that has been around for a while.
Semelka RC; Ramalho J; Vakharia A; AlObaidy M; Burke LM; Jay M; Ramalho M
Magn Reson Imaging; 2016 Dec; 34(10):1383-1390. PubMed ID: 27530966
[TBL] [Abstract][Full Text] [Related]
25. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi T; Takahashi S
Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
[TBL] [Abstract][Full Text] [Related]
26. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
27. Anaphylactic shock induced by gadoterate meglumine (DOTAREM).
Beaudouin E; Kanny G; Blanloeil Y; Guilloux L; Renaudin JM; Moneret-Vautrin DA
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):382-5. PubMed ID: 14768523
[TBL] [Abstract][Full Text] [Related]
28. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
Campos A; Aznar L; Alamar R; Castelló JV
Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
[No Abstract] [Full Text] [Related]
29. MultiHance for dynamic MR imaging of the breast.
Sardanelli F
Eur Radiol; 2004 Jun; 14 Suppl 7():O65-70; discussion O84-5. PubMed ID: 15503379
[No Abstract] [Full Text] [Related]
30. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
Runge VM
Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
[TBL] [Abstract][Full Text] [Related]
31. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
32. Fatal reaction to gadopentetate dimeglumine.
Jordan RM; Mintz RD
AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905
[No Abstract] [Full Text] [Related]
33. Laryngospasm after administration of gadopentetate dimeglumine.
Omohundro JE; Elderbrook MK; Ringer TV
J Magn Reson Imaging; 1992; 2(6):729-30. PubMed ID: 1446118
[TBL] [Abstract][Full Text] [Related]
34. Clinical safety of gadopentetate dimeglumine.
Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
[TBL] [Abstract][Full Text] [Related]
35. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale.
Choyke PL; Knopp MV
Radiology; 2003 Jun; 227(3):627-8. PubMed ID: 12773668
[No Abstract] [Full Text] [Related]
36. Nephrogenic systemic fibrosis and gadolinium: a perfect storm.
Colletti PM
AJR Am J Roentgenol; 2008 Oct; 191(4):1150-3. PubMed ID: 18806157
[No Abstract] [Full Text] [Related]
37. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications.
Niendorf HP; Alhassan A; Geens VR; Clauss W
Invest Radiol; 1994 Jun; 29 Suppl 2():S179-82. PubMed ID: 7928222
[No Abstract] [Full Text] [Related]
38. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
39. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
40. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors.
Murphy KP; Szopinski KT; Cohan RH; Mermillod B; Ellis JH
Acad Radiol; 1999 Nov; 6(11):656-64. PubMed ID: 10894068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
